


Int'l Application No.: PCT/EP00/05881

Int'l Filing Date: 23 June 2000

Applicants have amended claims 2-6 and 8 and have cancelled claims 9-15 and have added claims 16-19 to put the claims in conformity with U.S. practice. Support for claims 16-19 may be found in original claim 8. No new matter has been introduced.

Respectfully submitted,



Kathryn L. Sieburth  
Attorney for Applicant  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090

n:\KLS\cases\p32331\prelimamend.doc

10019105 122001

Int'l Application No.: PCT/EP00/05881  
Int'l Filing Date: 23 June 2000


531 Rec'd PCT/PTO 20 DEC 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

2. (Amended) A process for the preparation of a compound of formula (I) [as defined in] according to claim 1, or a salt thereof or a solvate thereof, [which] wherein said process comprises the steps of:

(a) [the] amidation of a [suitable] carboxylic acid having the formula:



wherein X', Y', Z', A', R1' and R2' each respectively represent X, Y, Z, A, R1 and R2 as defined in claim 1 or a protected form thereof,

with [a suitable] an amine having the formula:



wherein RS' and Rt' each respectively represent RS and Rt as defined in claim 1, or a protected form thereof, and


(b) optionally preparing a salt or a solvate thereof.

3. (Amended) A process for the preparation of a compound of formula (I) [as defined in claim 1, or a salt thereof or a solvate thereof, which process comprises the amidation of a compound of formula (II)


10019105-122001

Int'l Application No.: PCT/EP00/05881

Int'l Filing Date: 23 June 2000




wherein X', Y', Z', A', R<sub>1</sub>' and R<sub>2</sub>' each respectively represent X, Y, Z, A, R<sub>1</sub> and R<sub>2</sub> respectively as defined in relation to formula (I) as defined in claim 1 or a protected form thereof with a compound of formula (III)



wherein R<sub>S</sub>' and R<sub>T</sub>' represent R<sub>S</sub> and R<sub>T</sub> respectively as defined in relation to formula (I) as defined in claim 1 or a protected form thereof and thereafter, as necessary, carrying out one or more of the following steps;] according to claim 2, further comprising the steps of:

- (i) converting [one] the compound of formula (I) formed in step(a) or step (b) into another compound of formula (I);
- (ii) removing any protecting group; and
- (iii) preparing a salt or a solvate [of the compound so formed] thereof.

4. (Amended) A process for the preparation of a compound of formula (I) [as defined in] according to claim 1, or a salt thereof or a solvate thereof, [which] wherein said process comprises [the] cleavage of a compound of formula (VIII) at the N-Resin bond[.]



Int'l Application No.: PCT/EP00/05881

Int'l Filing Date: 23 June 2000

wherein X', Y', Z', A', R<sub>1</sub>', R<sub>2</sub>', and [Rs'] each respectively represent X, Y, Z, A, R<sub>1</sub>, R<sub>2</sub> and R<sub>s</sub> [Rs respectively as defined in relation to formula (I)] as defined in claim 1.

5. (Amended) A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof[, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.

6. (Amended) A method for the treatment [and/or] or prophylaxis of diseases associated with over activity of osteoclasts in mammals [which] wherein said method comprises the administration of an effective non-toxic amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

8. (Amended) A method for the treatment of tumours, [especially those related to renal cancer, melanoma, colon cancer, lung cancer and leukemia,] viral conditions [(for example those involving Semliki Forest, Vesicular Stomatitis, Newcastle Disease, Influenza A and B, HIV viruses)], ulcers [(for example chronic gastritis and peptic ulcer induced by Helicobacter pylori)], autoimmune diseases and transplantation, for the treatment [and/or] or prevention of hypercholesterolemic and atherosclerotic diseases, AIDS [and], Alzheimer's disease, and angiogenic diseases[, such as rheumatoid arthritis, diabetic retinopathy, psoriasis and solid tumours,] in a human or non-human mammal, which method comprises administering an effective, non-toxic, amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof or a

10019105 122001

Int'l Application No.: PCT/EP00/05881

Int'l Filing Date: 23 June 2000

pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

Please add new claims 16-19, as follows:

16. (New) The method according to claim 8, wherein the treatment of tumours comprises treatment of renal cancer, melanoma, colon cancer, lung cancer and leukemia.

17. (New) The method according to claim 8, wherein the treatment of viral conditions comprises treatment of Semliki Forest virus, Vesicular Stomatitis, Newcastle Disease, Influenza A and B and HIV viruses.

18. (New) The method according to claim 8, wherein the treatment of ulcers comprises treatment of chronic gastritis and peptic ulcers induced by *Helicobacter pylori*.

19. (New) The method according to claim 8, wherein the treatment of angiogenic diseases comprises treatment of rheumatoid arthritis, diabetic retinopathy, psoriasis and solid tumours.

10019105 122001